Incyte reported it continues to see promising results from trials that used a version of its blockbuster drug Jakafi in the treatment of Atopic dermatitis, a common type of skin disease.
New findings from the analyses presented at a research conference added to the growing body of evidence on ruxolitinib cream as a potential treatment for the disease, the company based near Wilmington reported.
“We are pleased to have the opportunity to share additional analyses from the TRuE-AD program with the scientific community at AAD VMX as these data provide more insight into the needs of people living with AD and the impact ruxolitinib cream could have across patient subgroups,” said Jim Lee, group vice president at Incyte. “Specifically, the findings suggest ruxolitinib cream could be an effective treatment option for AD irrespective of patients’ pre-treatment characteristics, and may be efficacious among those with more severe disease – potentially delaying or preventing the need for systemic therapy in these patients. We look forward to furthering analyzing data from the TRuE-AD program in the hopes it will lead to a meaningful new option for patients living with this inflammatory skin condition, which can significantly impact patients’ quality of life.”
“There is an urgent need for new treatment options that balance efficacy and tolerability for patients with atopic dermatitis,” said Kim Papp, M.D., Ph.D., founder and president of Probity Medical Research and the coordinating investigator for the TRuE-AD program. “I am thoroughly encouraged by findings from the TRuE-AD program and the potential ruxolitinib cream could have for patients whose everyday lives are impacted by the itch and inflammation associated with their disease.”
Atopic dermatitis (AD) is a chronic skin disease affecting more than 21 million people in the United States and is characterized by inflammation and intense itch. AD’s signs and symptoms include irritated and itchy skin that can cause red lesions that may ooze and crust. Patients with AD are also more susceptible to bacterial, viral, and fungal infections.